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INTRODUCTION:
This randomized controlled trial is designed to test whether short-term (1-2 months) HRT cessation will sufficiently lower breast density to decrease the proportion of women who receive a recommendation for additional evaluation following a screening mammogram, and to examine whether there is a trend by duration of HRT cessation. The study is being conducted at Group Health Cooperative, a managed health care organization with an organized breast cancer screening program. We are using automated to identify HRT users who are due for screening mammograms. Women are being recruited through mailed correspondence and telephone contact. We are projecting that we will recruit between 630-785 women to randomize to one of three HRT arms: 1) cessation two months before the screening mammogram, 2) cessation one month before, and 3) continued HRT use. We are measuring breast density using a computer assisted method. Mammography recall rates are being determined from an expert radiologist review of the mammograms. Both readers are blinded to HRT status. We will test whether: 1) HRT cessation 1 or 2 months before a screening mammogram reduces the likelihood of receiving a recommendation for additional evaluation (recall) compared to women who continue using HRT; 2) HRT cessation for 1 versus 2 months affects the likelihood of receiving a recommendation for additional evaluation; and 3) there is a greater change in breast density (to lower breast density) among women who stop HRT 1 or 2 months before a screening mammogram to those who do not stop HRT. Change in breast density will be measured as the difference between breast density on the screening mammogram before the trial (while on HRT) and during the trial. As part of this trial we will also evaluate: 1) women's tolerance (defined as continued cessation) for short-term (1-2 months) HRT cessation, 2) the rate of HRT re-initiation after participation in the trial, and 3) rates of reported adverse events (return of hot flashes, thromboembolic events within the first 6-months after re-initiation, and return of bleeding with reinitiation among previously amenorrheic women) across randomization groups.
BODY:
Over the past year, we received final study approval from the HSRRB and began recruitment in November 2005 (see below for additional information on IRB process).
Below we outline our progress on the scope of work (SOW)M outlined in our original proposal. Task A. Recruit 1500 women to participate in the trial
We had initially proposed to start recruiting women in the summer of 2003; however, it became clear that the originally proposed recruitment timeline was overly optimistic relative to the IRB review process. In our last annual report, we had expected to start recruiting in August 2004, which was delayed until November 2004, pending final HSRRB approval. Additionally, following the early termination of the estrogen plus progestin arm of the Women's Health Initiative, HRT use has decreased by 40% among members of GHC. Thus, recruitment is substantially behind schedule and the available pool of women has decreased. We are anticipating that we will be able to recruit between 630-785 women for the trial, assuming similar rates of refusal and withdrawal after agreement; these estimates are based on extending recruitment through May 2006. In terms of the tasks in our SOW, we have completed tasks 1-3 (recruitment plan, tracking database, and programs to identify women). "• As of May 31, 2005, we have mailed invitation letters to 1318 women "* Called 1119 to confirm eligibility and invite them to participate "* Contacted physicians that asked to be contacted regarding any of their patients "* Monitored and responded to all calls on our 1-800 number "* Addressed concerns that women have had regarding symptoms. "• To date, we have randomized 244 women: 83 to 1 month cessation; 81 to 2 month cessation and 80 to no cessation. o 19 women withdrew after consent and randomization: 7 in the 1 month cessation group; 10 in the 2 month cessation group; and 2 in the no cessation group. 
Task B. Develop Study Materials
We have developed all study materials and have received approval for all materials from the local IRB and the HSRRB. We have identified the advocacy board members, have met in person with them twice and have communicated via email.
Task C. Monitor the safety of HRT cessation and initiation
We formed our DSMB when the study began. We met with them for the first time in October 2003, at which point they approved all study materials and the prototype for our DSMB report. It was decided by the DSMB that they would review the study findings three times during the study. We are slated to have our first DSMB meeting with open and closed reports sometime between September and November 2004; approximately 6 months after the first study outcomes become available.
Task D. Study staff read all films for clinical interpretation and breast density measurements for the screening mammograms, blinded with respect to HRT status. Validate HRT cessation/use.
We will be completing the first review of mammograms for density and clinical assessment in June 2005. We have developed the data collection instrument for the clinical assessment form and the tracking database for the mammogram films. We have not yet started monitoring GHC automated pharmacy data for reinitiation, as there has not been sufficient follow-up time to monitor reinitiation. We also incorporated questions into our follow-up questionnaire that ask women to report their intention for restarting HRT and ask women about their compliance with HRT cessation during the study.
Task E. Data quality and control
The data collection instruments we have developed use Teleform technology. What this means is that our instruments are scanned into a computer that has built-in logic checks for the data. As a result, we will not be doing manual data entering of the questionnaires. We will complete the first mammogram readings (for density and clinical assessment) in June 2005. We will be incorporating data quality control measures that include a re-reading of films as we progress with our monthly readings.
Task F. Final analyses and report writing
We have not completed Task F, since both elements require data collection to be completed. "* Had a second meeting with our Advocacy Board. They reviewed suggested changes to the recruitment materials and made additional suggestions that we incorporated into our modification request.
KEY RESEARCH ACCOMPLISHMENTS:
Issues we have run into with obtaining IRB approval We have experience significant delays in start-up by trying to navigate demands from 2 different IRBs, which sometime had conflicting requests in the ways materials should be revised. Additionally, the delay in response time from submissions to HSRRB dramatically impacted our ability to start study recruitment. We have documented the timeline for all submissions to our local IRB and their responses (Appendix A) and have done the same for our submissions to HSRRB and their responses (Appendix B).
Our initial submission to and final approval from GHC and HSRRB is also summarized below. The communications both with our local IRB to comply with HSRRB requests and with HSRRB have consumed an enormous amount of staff time. Additionally, our local IRB has received complaints from the HSRRB about some of the processes that we have in place at GHC. These issues have resulted in GHC's IRB refusal to expedite any additional modification to any study materials in order ensure that there are no further issues or concerns from the HSRRB. This further delays our ability to make changes to any study materials or procedures as we continue recruitment.
REPORTABLE OUTCOMES:
We began recruiting women in November 2004. To date, we have no reportable outcomes.
CONCLUSIONS:
We are experiencing a higher proportion of refusals and withdrawal after agreeing to participate in the trial than is typical for GHC studies. We have spent considerable time talking with our survey department to determine ways we could improve the recruitment materials to address the concerns and/or questions of women who are refusing. We have made modifications to our recruitment materials that address the issues that our survey department has brought up: 1) how will participation directly influence women, and 2) what if women cannot comply with staying off their hormones if they are randomized to one of the 2 cessation arms. Our proposed revisions are being reviewed by the local IRB in June 2005 and we expect to be able to forward documentation of their approval to the HSRRB by the end of June 2005.
One of our key findings to date is that the cohort of women who are still using HRT following the results of the Women's Health Initiative (WHI) may be substantially different than women who were using before WHI. As such, understanding whether this intervention would be acceptable to women still using HRT is likely to become a major focus of this study. For example, if we find that women who stop using hormones have a significant reduction in breast density and/or recall rates, it may be that the intervention is still unacceptable to the majority of women who are still using HRT. We are collecting information on compliance, reinitiation and symptoms, so we will be well positioned to address acceptability of the intervention.
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